07:27 AM EDT, 07/15/2025 (MT Newswires) -- Procept BioRobotics ( PRCT ) said Monday its aquablation therapy received a Category 1 current procedural terminology code in the 2026 Medicare proposed Physician Fee Schedule, or PFS.

The procedure was assigned a total relative value unit of 16.14 that translates to a proposed national average physician payment of approximately $540 under the 2026 Medicare PFS, the company said.

Truist Securities said the reduction in physician payment was slightly worse than expected but in line with other resective procedures.

Truist maintained a buy rating on Procept BioRobotics ( PRCT ) with a $70 price target.